CTNM - Contineum Therapeutics, Inc.

QQQ $ 586.25 $ -1.08 (-0.18 %)

DIA $ 458.01 $ -1.42 (-0.31 %)

SPY $ 653.86 $ -1.09 (-0.17 %)

TLT $ 89.55 $ -0.11 (-0.12 %)

GLD $ 373.76 $ -0.23 (-0.06 %)

Previous Close

$ 12.22

Open

$ 11.37

Bid

$ 11.01 x 5

Ask

$ 11.19 x 100

Day's Range

$ 10.96 - $ 11.43

52 Week Range

$ 3.35 - $ 16.25

Volume

644,566

Average Volume

Market Cap

282.27M

Beta (5Y Monthly)

$ 0.59

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	10-30-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	05-14-2025	03-31-2025	10-Q
4	03-06-2025	01-01-1970	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-14-2024	06-30-2024	10-Q
7	05-16-2024	03-31-2024	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

RBC Capital Maintains Outperform on Contin...
11/21/2025 14:35:08

RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price tar...

Market-Moving News for November 21st
11/21/2025 12:16:49

CTNM: -20% | Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VIS...

Trading Halt: Halt status updated at 4:20:...
11/20/2025 21:20:05

Contineum Therapeutics Announces Phase 2 P...
11/20/2025 21:08:57

Trading Halt: Halted at 4:01:00 p.m. ET - ...
11/20/2025 21:01:04

Contineum Therapeutics Q3 EPS $(0.45) Beat...
10/30/2025 20:51:33

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate o...

this-lululemon-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday

This Lululemon Analyst Is No Longer Bullis...
09/25/2025 12:56:47

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Biogen Analyst Begins Coverage On A B...
09/25/2025 12:42:57

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Leerink Partners Initiates Coverage On Con...
09/25/2025 11:21:38

Leerink Partners analyst Faisal Khurshid initiates coverage on Contineum Therapeutics (NASDAQ: CTNM) with a Outperform ratin...

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

Contineum Therapeutics Reports Topline Dat...
09/18/2025 12:10:39

12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 17:06:05

Morgan Stanley Maintains Overweight on Con...
08/18/2025 13:10:26

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and raises the price ta...

Contineum Therapeutics Q2 EPS $(0.62) Miss...
08/05/2025 20:34:26

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

Contineum Therapeutics Completes PrMS And ...
06/25/2025 12:16:54

Contineum Therapeutics, Inc.

Morgan Stanley Maintains Overweight on Con...
05/19/2025 14:37:08

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Overweight and lowers the price ta...

RBC Capital Reiterates Outperform on Conti...
05/15/2025 16:20:57

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price...

Contineum Therapeutics Q1 EPS $(0.62) Miss...
05/14/2025 20:15:58

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate...

Jones Trading Initiates Coverage On Contin...
03/13/2025 16:34:59

Jones Trading analyst Debanjana Chatterjee initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Buy rating and ...